Ocular adverse events with immune checkpoint inhibitors

被引:77
作者
Fang, Tony [1 ]
Maberley, David A. [2 ]
Etminan, Mahyar [2 ]
机构
[1] Univ British Columbia, Fac Med, Med Undergrad Program, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada
关键词
Immune checkpoint inhibitors; Immunotherapy; Drug-induced; Uveitis; Eye inflammation; Disproportionality analysis; CANCER; BLOCKADE;
D O I
10.1016/j.joco.2019.05.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To quantify the risk of ocular adverse events with immune checkpoint inhibitors (ICIs) as reported to the Food and Drug Administration (FDA). Methods: Disproportionality analysis using data from U.S. FDA's Adverse Events Reporting System (FAERS) database 2003 to 2018. Data from pharmaceutical manufacturers, healthcare providers, consumers in the U.S., and post-marketing clinical trial reports from U.S. and non-U.S. studies. All cases of uveitis, dry eye syndrome, ocular myasthenia and eye inflammation with use of the following ICIs: atezolizumab, avelumab, cemiplimab, durvalumab, ipilimumab, nivolumab and pembrolizumab. Reported odds ratios (RORs) and corresponding 95% confidence intervals (CIs) were computed for all drugs as a group or as individual agents. Results: We identified 113 ocular adverse events for all ICIs of interest including uveitis, dry eye, ocular myasthenia and eye inflammation. Nivolumab had the highest number of adverse events (N = 68) associated with use of the ICI. Nivolumab had the highest association with ocular myasthenia [ROR = 22.82, 95% CI (7.18-72.50)] followed by pembrolizumab [ROR = 20.17, 95% CI (2.80-145.20)]. Among all ICIs approved in North America, atezolizumab had the highest association with eye inflammation [ROR = 18.89, 95% CI (6.07-58.81)] and ipilmumab had the highest association with uveitis [ROR = 10.54, 95% CI (7.30-15.22)]. Conclusion: The results of this disproportionality analysis suggest use of ICIs is associated with an increase risk for ocular adverse reactions. Future epidemiologic studies are needed to better quantify these adverse events. Copyright (C) 2019, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V.
引用
收藏
页码:319 / 322
页数:4
相关论文
共 15 条
[1]  
[Anonymous], OPENVIGIL 2 1 SOFTW
[2]  
[Anonymous], 2018, ANA 2018 143 ANN M A
[3]   Ocular and orbital side-effects of checkpoint inhibitors: a review article [J].
Antoun, Joelle ;
Titah, Cherif ;
Cochereau, Isabelle .
CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :288-294
[4]   Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy [J].
Bitton, Karen ;
Michot, Jean-Marie ;
Barreau, Emmanuel ;
Lambotte, Olivier ;
Haigh, Oscar ;
Marabelle, Aurelien ;
Voisin, Anne-Laure ;
Mateus, Christine ;
Remond, Anne-Laure ;
Couret, Chloe ;
Champiat, Stephane ;
Labetoulle, Marc ;
Rousseau, Antoine .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 202 :109-117
[5]   Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies [J].
Byun, David J. ;
Wolchok, Jedd D. ;
Rosenberg, Lynne M. ;
Girotra, Monica .
NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) :195-207
[6]   Checkpoint inhibitor-induced uveitis: a case series [J].
Conrady, Christopher D. ;
Larochelle, Marissa ;
Pecen, Paula ;
Palestine, Alan ;
Shakoor, Akbar ;
Singh, Ajay .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (01) :187-191
[7]   CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects [J].
Dalvin, Lauren A. ;
Shields, Carol L. ;
Orloff, Marlana ;
Sato, Takami ;
Shields, Jerry A. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (06) :1063-1078
[8]   Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials [J].
El Osta, B. ;
Hu, F. ;
Sadek, R. ;
Chintalapally, R. ;
Tang, S. -C. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 119 :1-12
[9]   Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors [J].
Hargadon, Kristian M. ;
Johnson, Coleman E. ;
Williams, Corey J. .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 :29-39
[10]   Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity [J].
Inno, Alessandro ;
Metro, Giulio ;
Bironzo, Paolo ;
Grimaldi, Antonio M. ;
Grego, Elisabetta ;
Di Nunno, Vincenzo ;
Picasso, Virginia ;
Massari, Francesco ;
Gori, Stefania .
TUMORI JOURNAL, 2017, 103 (05) :405-421